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Abstract: Lung cancer still represents the leading cause of cancer-related mortality. However, the recent 
advent of tyrosine kinase inhibitors (TKI), pioneering drugs against targetable mutations, have dramatically 
improved prognosis of advanced non-small cell lung cancer (NSCLC) patients. Anaplastic lymphoma kinase 
(ALK) gene rearrangements, identified in 3–7% of NSCLC cases, reflects in the constitutive activation 
of downstream signalling pathways, stimulating tumour cell proliferation, differentiation and survival. To 
accurately detect the wide spectrum of ALK rearrangements, the introduction of innovative techniques, like 
reverse transcriptase polymerase chain reaction (RT-PCR) or next generation sequencing (NGS) now allows 
for a more precise detection of variants and a more objective reading assessment, compared to the traditional 
diagnostic approaches. In some occasions, these new tools may dynamically monitor tumor evolution and 
even guide the choice of the most appropriate ALK inhibitor. In fact, among ALK TKIs available, crizotinib 
was the first to receive FDA accelerate approval for ALK rearranged NSCLC patients. Notwithstanding 
its response rate, ranging from 57% to 74%, the majority of patients progress within the first year of drug 
administration, due to acquired resistance. Both ALK-dependent and independent mechanisms of acquired 
resistance to TKIs have been identified. If the activation of multiple bypass signaling pathways constitutes 
the most common ALK-independent mechanism of resistance and one of the most difficult to overcome, 
ALK-dependent escape strategy mainly consists of mutations in the kinase domain, where the type of 
mutation largely depends on the TKI administered. Second and third generation TKIs are now available and 
are demonstrating high systemic and central nervous system (CNS) efficacy in clinical trials. Even though 
appropriate timing and sequencing of these compounds are still unclear, the large number of ALK inhibitors 
is now a precious resource aiming to prolong progression-free survival (PFS) and finally overall survival 
(OS). Here Authors provide an overview of the current approaches in the clinical management of advanced 
NSCLC patients harboring ALK rearrangement and discuss future perspectives to address current issues, 
highlighting the perception that ALK-rearranged advanced NSCLC patients benefit from maintained ALK 
inhibition for as long as possible.
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Introduction and molecular pathology of 
anaplastic lymphoma kinase (ALK)-rearranged 
non-small cell lung cancer (NSCLC)
Lung cancer is diagnosed in a large number of cases and, 
with 1.69 million deaths detected in 2015, it is the foremost 
cause of cancer-related death (1). Recently, pioneering 
drugs against molecular targets, primarily for patients 
with advanced NSCLC expressing epidermal growth 
factor receptor (EGFR) mutations, subsequently for those 
who presented ALK rearrangements, have considerably 
improved their prognosis (2).
ALK gene is placed on chromosome 2, it encodes for 
a trans-membrane tyrosine kinase receptor, the ALK, 
member of the insulin receptor super-family. ALK gene 
rearrangements were identified in 3–7% of NSCLC cases: 
the short-arm inversion (inv 2-p21p23) in chromosome 2 
produces a fusion of echinoderm microtubule-associated 
protein-like 4 (EML4) gene exons 1–13 with exons 20–29 
of ALK gene (2); this resulted EML4-ALK kinase induces 
a dimerization of ALK receptor in a ligand-independent 
manner, and a consequent constitutive activation of 
downstream signalling pathways as JAK/STAT (Janus 
kinase/signal transducer and activator of transcription), 
PI3K/AKT (phosphatidylinositol-3 kinase/protein 
kinase B) and MAPK/ERK (mitogen-activated kinase-
like protein/extracellular-signal regulated kinase) ones, 
inducing cell proliferation, differentiation and survival (3). 
Rearrangement of EML4-ALK is more frequently expressed 
in younger patients, non-smokers, in signet-ring cell 
adenocarcinomas of Caucasian patients and acinus forms 
of adenocarcinomas of Asian ones. The alteration usually 
occurs independently of KRAS (Kirsten-rat-sarcoma) or 
EGFR mutations and, even within a very small amount of 
cases, it is not mutually exclusive, meaning that subjects 
harbouring EGFR mutations should not be ruled out from 
ALK baseline evaluation. Ultimately and differently from 
EGFR mutations, EML4-ALK rearrangement presents 
comparable incidence worldwide (4). ALK intracellular 
tyrosine kinase domain,  fusing with other EML4 
truncations, produces also variants which include the entire 
ALK intracellular domain, codified by exons 20 to 29, but 
differ in EML4 gene point of fusion (4). However, EML4 
is not an exclusive fusion partner with ALK as different 
even if unusual companions like KIF5B (kinesin family 
member 5B), TFG (TRK-fused gene), or KLC1 (kinesin 
light chain 1), were also evidenced (5).
For an accurate detection of ALK rearrangements, in 
clinical practice, the association of a fluorescent in situ 
hybridization (FISH) technique with immunohistochemistry 
(IHC) is currently recommended and can be performed 
on either histological or cytological specimens (5). FISH 
test was the first procedure to be described as the gold 
standard and the companion diagnostic in FDA crizotinib 
approval. With the advent of anti-ALK antibodies, IHC 
demonstrated to be a viable option, also in those cases 
with small tissue samples, with the advantage, compared 
to FISH, to be reproducible, cost and time effective. The 
most extensively used antibodies are D5F3 (Cell Signaling 
Technology, Danvers, MA, USA) and 54A (Novocastra, 
Leica Biosystems, Buffalo Grove, IL, USA) clones (6). 
Comparatives analyses were carried out for IHC, especially 
with D5F3 clone, and FISH, reporting high concordance 
(sensitivity ranged from 81% to 100% and specificity from 
82% to 100%, respectively), according to the different 
studies considered (7). In any case, the diagnostic tools just 
mentioned have several limitations: FISH test results could 
be affected by inappropriate sample fixation or false negative 
results could be evidenced in those cases of complex ALK 
rearrangements. Similarly, IHC pitfalls could often be due 
to misinterpretation in labelling reading (influenced by 
necrotic areas, macrophages in tumor specimen or delay 
in fixation) with the risk of false positive results. Moreover, 
important limitations are common to both the approaches 
and lie in tumor heterogeneity, subjectivity in result 
assessments and inability to detect uncommon variants (7). 
Innovative techniques like reverse transcriptase 
polymerase chain reaction (RT-PCR) or next generation 
sequencing (NGS) were then improved and now allow 
to face these issues, at least in part: multiplexed RT-PCR 
consents to identify pre-defined ALK fusion gene variants 
but the clinical utility of this tool has been questioned due to 
the high costs, expertise needed, bias derived by the quality 
and quantity of extracted RNA and finally the suboptimal 
performance on formalin-fixed paraffin-embedded tissue 
sections (8). NGS rapidly detects all spectrum of ALK 
rearrangements and simultaneously identifies further gene 
mutations/translocations that may interfere with treatment 
choices (e.g., ROS-1, c-ROS oncogene 1, RET rearranged 
during transfection, MET proto-oncogene). Tumor 
sequencing can also clarify discordant results between 
IHC and FISH, more common in cases of borderline 
FISH positivity (15–20%) (7). An additional advantage is 
NGS application on blood samples (liquid biopsy), with 
the aim to partially solve tumor heterogeneity issues while 
dynamically monitoring tumor evolution, particularly along 
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ALK inhibitors administration (9). 
Options of treatment and acquired resistance 
for advanced ALK-rearranged NSCLC patients
Treatment of ALK-dependent NSCLC typically starts 
with an ALK tyrosine kinase inhibitor (TKI). Crizotinib is 
a multi-target MET, ALK and ROS1 TKI; its efficacy was 
described in PROFILE 1014, a front-line phase III trial 
which showed a 10.9 versus 7 months [hazard ratio (HR): 0.45, 
95% confidence interval (CI), 0.35–0.60 P<0.0001] benefit 
in progression-free survival (PFS) and a 74% versus 45% 
objective response rate (ORR) compared to standard first-line 
platinum/pemetrexed chemotherapy in patients with ALK-
rearranged NSCLC, receiving, for this reason, accelerate 
approval from US Food and Drug Administration (FDA) (10).
However, even if crizotinib, as first-generation ALK 
inhibitor, presents an ORR ranging from 57% to 74%, the 
majority of patients progress within the first 12 months, 
with 11.3 months as a median duration of response. In this 
context two major mechanisms of acquired resistance to 
ALK TKIs were identified: (I) ALK-dependent: where cell 
addiction from ALK signalling endures even with presence 
of ALK amplification or resistance mutations; and (II) ALK-
independent: such as by-pass signaling, drug efflux pumps 
or phenotypic changes like epithelial-to-mesenchymal 
transition (11). Primary resistance mechanisms were also 
documented, but for now they are poorly understood and 
currently under evaluation (11). Regarding ALK-dependent 
acquired resistance, it mainly consists of mutations in the 
kinase domain, whilst ALK gene amplification is a pretty 
uncommon event in patients progressing to crizotinib. 
In contrast with EGFR gatekeeper mutation T790M, in 
ALK rearranged NSCLC patients the type of mutation 
largely depends on the TKI administered, particularly in 
crizotinib-resistant patients usual alterations are G1269A 
or L1196M (whereas the first engages the crizotinib 
binding site, the latter affects the catalytic domain in the 
ATP pocket), G1202R ALK mutation is present in around 
2% of patients progressing to crizotinib but it induces 
resistance also to next-generation ALK TKIs (ceritinib, 
alectinib and brigatinib) while it is proficiently inhibited 
by lorlatinib, a third-generation inhibitor (11). Wild-type 
EML4-ALK amplifications or those of ALK fusion gene 
(about 13%) induce acquired drug resistance independently 
from concurrent ALK mutations (e.g., concomitant ALK 
CNG and G1269A mutations reported in one patient) (12).
Among ALK-independent mechanisms of resistance, 
creation of multiple pathways for by-passing the signal is 
the most common escape strategy and represents one of 
the most difficult to overcome. Pathways involved include 
KRAS mutations and EGFR, RAS/MEK (rat-sarcoma/
mitogen-activated protein-kinase), HSP90 (heat-shock-
protein-90) or PI3K/AKT/mTOR (PI3K/AKT/mammalian 
target of rapamycin) pathways, phospho-EGFR, phospho-
ALK, phospho-HER3 (human epidermal growth factor 
receptor-3) or phospho-IGFR-1R (insulin-like growth 
factor-1 receptor) overexpressions, and amplifications 
of KIT (KIT proto-oncogene receptor tyrosine kinase). 
Multidrug resistance 1 (MDR1)  gene encodes for 
P-glycoprotein (P-gp), a highly-conserved ATP-dependent 
efflux pump which is a mechanism of resistance often 
responsible for central nervous system (CNS) disease 
progression. Finally, epithelial-to-mesenchymal transition 
represents an acquired resistance mechanism also described 
in patients receiving ceritinib, but still under evaluation (12).
In this context, it is important to highlight an interesting, 
innovative molecular concern: dissimilar EML4-ALK fusion 
variants predict different responses and/or disease control to 
ALK inhibitor crizotinib; this event is due to protein stability 
from EML4-ALK variants which influences the overall 
fusion stability, even also protein degradation induced 
by the inhibitor used and its consequent drug sensitivity. 
Particularly, it was evidenced that EML4-ALK variant 1 
induces a similar ORR to crizotinib (74% versus 63%) 
but a higher disease control rate (DCR, 95% versus 63%) 
and a prolonged PFS (11 versus 4.2 months) than other 
variants (13). Woo et al. evidenced, for variants 1/2/others 
group, a 2-year PFS of 69% (95% CI, 49.9–95.4%) versus 
32.7% (95% CI, 15.6–68.4%) of group variants 3a/b 
(P=0.10) among crizotinib-, ceritinib- and alectinib-treated 
patients. Cells with variant 3a or 5a were refractory to 
ALK TKI with >10-fold higher half maximal inhibitory 
concentration in vitro (14).
Considering previous reasons, next-generation ALK 
inhibitors development was enhanced and ceritinib 
(LDK378),  alectinib (CH5424802) and brigatinib 
(AP26113) obtained FDA approval for treatment of ALK-
rearranged NSCLC patients refractory to crizotinib; 
subsequently lorlatinib (PF-06463922) received a 
breakthrough-therapy designation in the same setting. 
Innovative ALK TKIs as ensartinib (X-396) or entrectinib 
(RXDX-101) are presently under clinical evaluation (15) 
(Table 1).
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Table 1 Ongoing trials with ALK TKIs as monotherapy in NSCLC
ALK TKI Study title Phase ClinicalTrials.gov identifier
Crizotinib A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib 
in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
Obs NCT03647111
Crizotinib Prospective Observational Study To Identify Patients With Advanced/
Metastatic NSCLC And ALK Translocation And To Establish Their Therapeutic 
Management (Idealk)
Obs NCT02679170
Crizotinib A Randomized Phase III Trial for Surgically Resected Early Stage Non-small 
Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors 
Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
III NCT02201992
Crizotinib A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients 
With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small 
Cell Lung Cancer
II NCT03088930
Ceritinib A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy 
and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small 
Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
II NCT02336451
Ceritinib A Multi-center, Randomized Open Label Study to Assess the Systemic 
Exposure, Efficacy, and Safety of 450 mg Ceritinib Taken With a Low-fat 
Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With 
That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK 
Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
I NCT02299505
Ceritinib Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation in 
ALK-rearranged Metastatic Lung Adenocarcinoma
II NCT02513667
Brigatinib Brigatinib in Patients with Anaplastic Lymphoma Kinase-Positive (ALK+), 
Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or 
Ceritinib
II NCT03535740*
Brigatinib Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors 
in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
II NCT02706626  
Brigatinib A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients 
With ALK-Positive Non-Small Cell Lung Cancer (NSCLC
II NCT03410108
Brigatinib A Phase 3 Randomized Open-label Study of Brigatinib (Alunbrig®) Versus 
Alectinib (Alecensa®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-
Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (Xalkori®)
III NCT03596866*
Brigatinib Pulmonary Physiology and Systemic Inflammatory Signature Investigations in 
Early Onset Pulmonary Events Associated with Brigatinib Use in Non-Small 
Cell Lung Cancer
Obs NCT03389399
Brigatinib Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors 
in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
II NCT02706626
Alectinib A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and 
Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in 
Patients with Completely Resected Stage IB (Tumors Equal to or Larger Than 
4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung 
Cancer
III NCT03456076*
Alectinib Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma 
Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung 
Cancer
Obs NCT03271554
Table 1 (continued)
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Table 1 (continued)
ALK TKI Study title Phase ClinicalTrials.gov identifier
Alectinib An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy 
and Safety of Alectinib in Patients With ALK-Rearranged Non−Small Cell Lung 
Cancer After Disease Progression on Prior ALK Inhibitor Therapy
II NCT03155009
Lorlatinib A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) 
Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of 
Patients With Advanced Alk-positive Non-small Cell Lung Cancer
III NCT03052608
Lorlatinib A Phase II Study of Lorlatinib (PF-06463922) in Advanced Anaplastic 
Lymphoma Kinase (ALK) and ROS Proto-Oncogene 1 (ROS1) Rearranged 
Non-Small Cell Lung Cancer (NSCLC) With Central Nervous System (CNS) 
Metastasis in the Absence of Measurable Extracranial Lesions
II NCT02927340
Lorlatinib A Phase 3, Randomized, Open-label Study of Lorlatinib (Pf-06463922) 
Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of 
Patients With Advanced Alk-positive Non-small Cell Lung Cancer
III NCT03052608
Ceritinib/
alectinib/
brigatinib/other
An Observational Parallel Group Phase 4 Study to Determine Progression-Free 
Survival and Evaluate Patient Experience for Patients with Metastatic ALK+ 
Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors
IV NCT03546894
Ensartinib Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in 
Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer 
(NSCLC) Patients
III NCT02767804
*, not yet recruiting. Obs, observational; TKI, tyrosine kinase inhibitor.
New generation ALK inhibitors 
The first ALK inhibitor approved by FDA for refractory 
ALK-rearranged advanced NSCLC patients to a prior ALK 
TKI was ceritinib and, as evidenced by enzymatic essays, 
it is considered twenty times more effective compared to 
crizotinib (16). In ASCEND-1 phase I trial, 83 ALK-
rearranged NSCLC patients who became resistant to crizotinib 
were enrolled in the dose-escalation phases with ceritinib. 
Investigators described a 58% ORR (95% CI, 48–67%) 
with a median PFS of 7 months (95% CI, 5.6–9.5 months). 
Importantly, all 19 patients for whom tumor samples were 
available at crizotinib progression responded to ceritinib, 
independently of the acquired resistance mechanism. 
Considering these data, the study suggested that high 
responses were induced by ceritinib in those subjects who 
became refractory to crizotinib. However, in the subsequent 
evaluations, specifically in ASCEND-2 and ASCEND-5, 
respectively, despite similar numbers of patients undergone 
to ceritinib, the percentage of those heavily pre-treated 
(56% versus 11%, equal or more than three prior lines 
of treatment), a higher proportion of them with brain 
metastasis (71% versus 57%), median PFS achieved with 
ceritinib calculated by independent review committee (IRC) 
was progressively shorter from ASCEND-1 to ASCEND-2 
to ASCEND-5, dropping from 7.2 to 5.4 months (17). In 
the meantime, in both ASCEND-4 trial, which compared 
ceritinib to platinum/pemetrexed first-line chemotherapy 
and in ALEX one, which compared alectinib to crizotinib 
in patients with ALK-rearranged NSCLC, positive data 
emerged but median PFS in ceritinib study was 16.8 months 
versus alectinib one which reached 25.7 months, by IRC 
(18,19).
Alectinib (RO5424802/CH5424802) is a second-
generation, ATP-competitive ALK TKI, specifically 
designed to overcome crizotinib resistance. Unlike 
crizotinib, alectinib is not able to inhibit ROS1 or MET 
while it reduces RET activity with a comparable potency 
to that of ALK. In vitro alectinib has a 3-fold increase ALK 
inhibition compared to crizotinib (to date 53 and 150.8 
nM, respectively). Moreover in vitro alectinib is efficient in 
treating several crizotinib-resistant ALK mutations, such 
as C1156Y, F1174L, L1196M or R1275Q. In the same 
context, it also proved its efficacy against ALK-mutant 
ceritinib-resistant L1198F and moderate potency against 
composite mutations such as D1203N+F1174C (20).
As evidenced in vitro studies and unlike crizotinib and 
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ceritinib, alectinib is not a substrate of the key efflux 
transporter, P-gp. This could clarify its higher concentration 
in cerebrospinal fluid (CSF) (close to 0.75  ng/mL) compared 
to crizotinib (0.616 ng/mL, as reported by Costa et al.) 
supporting its suggested activity also in ALK-rearranged 
NSCLC patients with leptomeningeal disease (21). The 
phase III ALEX trial, comparing first-line alectinib to 
crizotinib in advanced ALK-rearranged NSCLC patients, 
confirmed a higher response rate (82.9% versus 75.5%), 
a higher 12-month event-free survival rate (68.4% versus 
48.7%) with a lower probability of progressive disease (41% 
versus 68%) and particularly CNS progression (12% versus 
45%) with a lower rate of AEs (41% versus 50%). Median 
PFS has not yet been reached with alectinib (95% CI, 
17.7 months to not estimated) and was 11.1 months with 
crizotinib (95% CI, 9.1–13.1 months) (19). 
Finally, if eventually a CNS progression arises under 
alectinib administration, Gainor et al. reported that dose 
escalation with alectinib (900 mg twice daily) was able to re-
induce CNS tumor response in two ALK-positive NSCLC 
patients who presented CNS relapse on alectinib standard 
dose (600 mg twice daily), suggesting that dosing strategies 
could eventually overcome reduced CNS activity (22). 
Brigatinib (AP26113) was developed as a second-
generation ALK TKI. It is able to inhibit both ALK and 
EGFR with also EGFR T790M and ALK L1196M mutants 
as showed in pre-clinical and first-in-human studies. 
Brigatinib was evaluated with two different regimens in a 
phase II trial including crizotinib-refractory ALK-rearranged 
NSCLC patients who were then randomized to oral 
brigatinib 90 mg once daily (arm A) or brigatinib 180 mg 
once daily (arm B) with a 7-day lead-in at 90 mg. Median 
PFS as assessed by investigators was 9.2 and 12.9 months 
(95% CI, 7.4–15.6 months and 95% CI, 11.1 months to not 
reached) in arms A and B, respectively. ORR as assessed by 
investigators was 45% and 54% (97.5% CI, 34–56% and 
97.5% CI, 43–65%) in arms A and B, respectively (23). To 
date, in a recent press release of July 2018 from the global 
phase III ALTA-1L (ALK in lung cancer trial of AP26113 
in 1st-line) randomized trial, investigators communicated 
that brigatinib too, at the first pre-specified interim analysis, 
reached its primary endpoint, evidencing a statistically 
significant advantage, compared to crizotinib, in PFS in 
naïve ALK-rearranged advanced NSCLC patients (24). 
Finally, third-generation inhibitors are rising and 
lorlatinib (PF-06463922) as a reversible, potent ALK and 
ROS1 ATP-competitive inhibitor is one of them. In both 
vitro and xenograft models it demonstrated to be active in 
crizotinib-resistant cancers as well as against several resistant 
mutations in pre-clinical studies. In recently presented early 
phase II data a clinically meaningful activity was evidenced 
with substantial intracranial efficacy, particularly among 
patients harbouring ALK or ROS1 rearrangement and 
who were either treatment-naïve or failed a previous ALK 
inhibitor (25). 
Conclusions
Considering previous data, the large number of ALK 
inhibitors is now a precious resource aiming to prolong 
PFS and finally OS, highlighting the perception that 
ALK-rearranged advanced NSCLC patients benefit from 
maintained ALK inhibition for as long as they possibly can. 
Integrated treatments for oligo-metastatic disease and CNS 
progression, beyond-progression approaches, rechallenges 
or optimal treatment sequences based on resistance 
mechanisms should be specifically defined for every single 
patient.
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